Research Triangle Park, NC (PRWEB) June 19, 2013
North Carolina-based life sciences company Entegrion, Inc., announced organizational adjustments to advance development of its technologies.

Entegrions Executive Chairman John B. Mowell said, To assistance the advanced improvement of our product candidates Entegrions Board of Directors has created modifications to the Companys management structure and engaged industry leaders as important advisors.

The Firm announced that Michael Galiger will serve as Vice President of Operations with major responsibility for improvement of Entegrions plasma product Resusix, as well as supporting the continued advancement of the Companys other technologies. Mikes technical background, intensive operate with the improvement of Entegrions products, and his success in attracting a strong product development team, such as Stacy Hammonds as Director of Clinical Operations, and Taegen Sullivan, Item Improvement Engineer, have created a substantial contribution to Entegrions good results, Mowell continued.

Entegrion also announced the formation of a clinical advisory Board initially comprised of Paul Ness, MD, Director of Transfusion Medicine at Johns Hopkins Professor Peter Rhee, MD, Chief of Trauma, Vital Care, Burns and Emergency Surgery, University of Arizona Edward Scott, MD, President of Key Biologics and Philip C. Spinella, MD, Director, Pediatric Vital Care Translational Analysis Program, Washington University, St. Louis.

We are immensely proud to be linked with these world-class leaders in transfusion and trauma medicine. Drs. Rhee and Spinella each came out of the Armed Forces and served in Iraq. They will bring a distinctive user point of view to our technologies. Dr. Scott has decades of expertise with the supply of blood and blood derivatives, and Dr. Ness is an specialist in transfusion medicine. Their guidance will be invaluable as our biologic and health-related device technologies move into sophisticated development, Mowell stated.

Entegrion also announced that Richard Martin will serve as Executive Vice President with responsibility for Entegrions general day-to-day organization operations reporting to the Executive Chairman, and will assist in the places of strategic corporate arranging and improvement. Susan Reyer, the Companys Controller for the previous five years, now serves as Vice President, Chief Financial Officer, with duty for the Companys monetary and administrative matters.

Joseph DaCorta will continue in his part as Chief Technology Officer, with duty for managing Entegrions government relations and exploring new opportunities to use the Companys technologies. Arthur Bode continues to serve as Vice President, Chief Science Officer in charge of scientific research and project assistance.

Mowell stated, We are fortunate that every of the senior members of our management team have been integral to the companys operations for a number of years, positioning Entegrion effectively for continued accomplishment.

More than the previous three years, Entegrion has announced Division of Defense contract awards totaling a lot more than $ 50 million for the improvement of resuscitation and coagulation technologies that have critical healthcare applications for US Armed Forces.

About Entegrion
Entegrion, Inc. is a life sciences product development organization that is focused on improving the security and availability of the worlds blood supply. Primarily based in North Carolinas Research Triangle Park, Entegrion provides patented technologies designed to overcome limitations in storage, security, and availability of blood-derived goods whilst preserving their functionality. Numerous of Entegrions advances in biologics are primarily based on close collaborations with major medical study institutions. Check out http://www.entegrion.com for a lot more information.





A lot more Administrator Press Releases